Security
Entera Bio Ltd. Ordinary Shares · ENTX
ENTXNASDAQCommon stockCurrentCIK 1638097Updated Oct 7, 2026
ENTX price & chart
Loading TradingView…
NASDAQ:ENTX on TradingView ↗In the news
Correction: Entera to Participate in Upcoming Fall Investor Conferences ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
PRE 14A filing
EFFECT filing
424B3 filing
S-3 filing
Show 5 more recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
D filing
Items 06b
4 filing
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 15,993,000Source | 9,390,000Source | 11,765,000Source | 13,127,000Source |
| Property, Plant and Equipment, NetUSD | 134,000Source | 57,000Source | 100,000Source | 139,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,108,000Source | 8,660,000Source | 11,019,000Source | 12,309,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 0Source | 126,000Source | 0Source | 246,000Source |
| Assets, CurrentUSD | 15,298,000Source | 8,972,000Source | 11,257,000Source | 12,849,000Source |
| Operating Lease, Right-of-Use AssetUSD | 465,000Source | 275,000Source | 388,000Source | 90,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,892,000Source | 1,310,000Source | 1,379,000Source | 1,373,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,000Source | 1,000Source | 1,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -125,366,000Source | -113,927,000Source | -104,386,000Source | -95,497,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 41,000Source | 41,000Source | 41,000Source | 41,000Source |
| Stockholders' Equity Attributable to ParentUSD | 13,101,000Source | 8,080,000Source | 10,386,000Source | 11,754,000Source |
| Additional Paid in Capital, Common StockUSD | 138,425,000Source | 121,965,000Source | 114,730,000Source | 107,210,000Source |
| Liabilities and EquityUSD | 15,993,000Source | 9,390,000Source | 11,765,000Source | 13,127,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,203,000Source | 1,176,000Source | 1,091,000Source | 1,341,000Source |
| Operating Lease, Liability, CurrentUSD | 230,000Source | 170,000Source | 134,000Source | 91,000Source |
| Accounts Payable, CurrentUSD | 448,000Source | 132,000Source | 83,000Source | 17,000Source |
| Operating Lease, Liability, NoncurrentUSD | 260,000Source | 102,000Source | 256,000Source | 0Source |
| Other Liabilities, NoncurrentUSD | 393,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,750,000Source | 2,556,000Source | 1,689,000Source | 2,247,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -126,000Source | 126,000Source | -246,000Source | 63,000Source |
| Increase (Decrease) in Accounts PayableUSD | 316,000Source | 49,000Source | 66,000Source | -149,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 14,000Source | 29,000Source | 174,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -7,370,000Source | -6,818,000Source | -7,310,000Source | -12,499,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -107,000Source | -3,000Source | -17,000Source | -102,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 107,000Source | 3,000Source | 17,000Source | 47,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 13,710,000Source | 4,476,000Source | 6,036,000Source | 13,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 6,197,000Source | -2,345,000Source | -1,291,000Source | -12,588,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 14,973,000Source | 8,740,000Source | 11,085,000Source | 12,376,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | — | — | 0Source | 165,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -36,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,750,000Source | 2,556,000Source | 1,689,000Source | 2,247,000Source |
| DepreciationUSD | 30,000Source | 46,000Source | 56,000Source | 64,000Source |
| General and Administrative ExpenseUSD | 5,525,000Source | 5,095,000Source | 4,430,000Source | 7,253,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 14,000Source | 29,000Source | 137,000Source |
| Net Income (Loss) Attributable to ParentUSD | -11,439,000Source | -9,541,000Source | -8,889,000Source | -13,071,000Source |
| Nonoperating Income (Expense)USD | 90,000Source | 58,000Source | 31,000Source | 83,000Source |
| Operating ExpensesUSD | 11,529,000Source | 9,594,000Source | 8,891,000Source | 13,050,000Source |
| Proceeds from Issuance of Common StockUSD | 6,254,000Source | 3,960,000Source | 5,000Source | 0Source |
| Proceeds from Stock Options ExercisedUSD | 20,000Source | 749,000Source | 0Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 42,000Source | 181,000Source | 0Source | 134,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 398,000Source | — | — | — |
| Operating Income (Loss)USD | -11,529,000Source | -9,585,000Source | -8,891,000Source | -13,017,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -11,439,000Source | -9,527,000Source | -8,860,000Source | -12,934,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 14,000Source | 29,000Source | 137,000Source |
| Net Income (Loss) Attributable to ParentUSD | -11,439,000Source | -9,541,000Source | -8,889,000Source | -13,071,000Source |
| Earnings Per Share, BasicUSD per share | 0.25Source | 0.25Source | 0.31Source | 0.45Source |
| Earnings Per Share, DilutedUSD per share | 0.25Source | 0.25Source | 0.31Source | 0.45Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 46,191,067Source | 37,650,179Source | 29,007,794Source | 28,808,090Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 46,191,067Source | 37,650,179Source | 29,007,794Source | 28,808,090Source |
| Additional Financial Items | ||||
| Business Combination, Acquisition Related CostsUSD | 2,095,000Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | -37,000Source |
| General and Administrative ExpenseUSD | 5,525,000Source | 5,095,000Source | 4,430,000Source | 7,253,000Source |
| Gross ProfitUSD | 0Source | 9,000Source | 0Source | 33,000Source |
| Labor and Related ExpenseUSD | 1,597,000Source | — | — | — |
| Nonoperating Income (Expense)USD | 90,000Source | 58,000Source | 31,000Source | 83,000Source |
| Operating ExpensesUSD | 11,529,000Source | 9,594,000Source | 8,891,000Source | 13,050,000Source |
| Other ExpensesUSD | 334,000Source | — | — | — |
| Research and Development ExpenseUSD | 6,004,000Source | 4,499,000Source | 4,510,000Source | 5,848,000Source |
Offerings
Registration 333-298485
Registration 333-295710
Filing attachments
ea030045501ex99-1.htm · SCHEDULE 13G · 2026-08-04
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of th…
Read attachment ↗ex107.htm · S-3 · 2026-05-08
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 Entera Bio Ltd Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee …
Read attachment ↗